Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma

Nasr Alrabadi, Natasha Gibson, Kendra Curless, Liang Cheng, Matthew Kuhar, Shaoxiong Chen, Simon Warren, Ahmed K. Alomari

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Dedifferentiated metastatic melanoma can pose a significant diagnostic challenge, especially if the history of primary melanoma is not known or is remote. BRAF and NRAS mutations are common melanoma driver mutations that are usually sequenced to evaluate for treatment targets. We evaluated whether BRAF and NRAS mutational testing could contribute to the diagnosis of dedifferentiated metastatic melanoma when immunostains are negative. Seven patients with melanoma who had an additional diagnosis of poorly differentiated sarcoma with negative melanocytic immunostains were tested for BRAF and NRAS mutations. Three patients showed identical BRAF mutations in the melanoma and the poorly differentiated sarcoma and hence were re-classified as metastatic dedifferentiated melanoma. In these three patients, there was an average delay of 7 months before appropriate testing, workup and treatment for metastatic melanoma was initiated. Two of these patients currently have stable metastatic disease and show sustained therapeutic response to melanoma-specific treatment including BRAF inhibitors. BRAF mutational analysis should therefore be considered in cases of poorly differentiated sarcoma, especially if there is a known history of melanoma or with unusual localization of disease. The administration of melanoma-specific treatments in such dedifferentiated cases can show therapeutic response, highlighting the importance of rendering accurate diagnoses on such cases.

Original languageEnglish (US)
JournalModern Pathology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Melanoma
Mutation
Therapeutics
Sarcoma
History

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. / Alrabadi, Nasr; Gibson, Natasha; Curless, Kendra; Cheng, Liang; Kuhar, Matthew; Chen, Shaoxiong; Warren, Simon; Alomari, Ahmed K.

In: Modern Pathology, 01.01.2018.

Research output: Contribution to journalArticle

@article{6f3a946a922445b9ba790241706281a8,
title = "Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma",
abstract = "Dedifferentiated metastatic melanoma can pose a significant diagnostic challenge, especially if the history of primary melanoma is not known or is remote. BRAF and NRAS mutations are common melanoma driver mutations that are usually sequenced to evaluate for treatment targets. We evaluated whether BRAF and NRAS mutational testing could contribute to the diagnosis of dedifferentiated metastatic melanoma when immunostains are negative. Seven patients with melanoma who had an additional diagnosis of poorly differentiated sarcoma with negative melanocytic immunostains were tested for BRAF and NRAS mutations. Three patients showed identical BRAF mutations in the melanoma and the poorly differentiated sarcoma and hence were re-classified as metastatic dedifferentiated melanoma. In these three patients, there was an average delay of 7 months before appropriate testing, workup and treatment for metastatic melanoma was initiated. Two of these patients currently have stable metastatic disease and show sustained therapeutic response to melanoma-specific treatment including BRAF inhibitors. BRAF mutational analysis should therefore be considered in cases of poorly differentiated sarcoma, especially if there is a known history of melanoma or with unusual localization of disease. The administration of melanoma-specific treatments in such dedifferentiated cases can show therapeutic response, highlighting the importance of rendering accurate diagnoses on such cases.",
author = "Nasr Alrabadi and Natasha Gibson and Kendra Curless and Liang Cheng and Matthew Kuhar and Shaoxiong Chen and Simon Warren and Alomari, {Ahmed K.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41379-018-0161-0",
language = "English (US)",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma

AU - Alrabadi, Nasr

AU - Gibson, Natasha

AU - Curless, Kendra

AU - Cheng, Liang

AU - Kuhar, Matthew

AU - Chen, Shaoxiong

AU - Warren, Simon

AU - Alomari, Ahmed K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Dedifferentiated metastatic melanoma can pose a significant diagnostic challenge, especially if the history of primary melanoma is not known or is remote. BRAF and NRAS mutations are common melanoma driver mutations that are usually sequenced to evaluate for treatment targets. We evaluated whether BRAF and NRAS mutational testing could contribute to the diagnosis of dedifferentiated metastatic melanoma when immunostains are negative. Seven patients with melanoma who had an additional diagnosis of poorly differentiated sarcoma with negative melanocytic immunostains were tested for BRAF and NRAS mutations. Three patients showed identical BRAF mutations in the melanoma and the poorly differentiated sarcoma and hence were re-classified as metastatic dedifferentiated melanoma. In these three patients, there was an average delay of 7 months before appropriate testing, workup and treatment for metastatic melanoma was initiated. Two of these patients currently have stable metastatic disease and show sustained therapeutic response to melanoma-specific treatment including BRAF inhibitors. BRAF mutational analysis should therefore be considered in cases of poorly differentiated sarcoma, especially if there is a known history of melanoma or with unusual localization of disease. The administration of melanoma-specific treatments in such dedifferentiated cases can show therapeutic response, highlighting the importance of rendering accurate diagnoses on such cases.

AB - Dedifferentiated metastatic melanoma can pose a significant diagnostic challenge, especially if the history of primary melanoma is not known or is remote. BRAF and NRAS mutations are common melanoma driver mutations that are usually sequenced to evaluate for treatment targets. We evaluated whether BRAF and NRAS mutational testing could contribute to the diagnosis of dedifferentiated metastatic melanoma when immunostains are negative. Seven patients with melanoma who had an additional diagnosis of poorly differentiated sarcoma with negative melanocytic immunostains were tested for BRAF and NRAS mutations. Three patients showed identical BRAF mutations in the melanoma and the poorly differentiated sarcoma and hence were re-classified as metastatic dedifferentiated melanoma. In these three patients, there was an average delay of 7 months before appropriate testing, workup and treatment for metastatic melanoma was initiated. Two of these patients currently have stable metastatic disease and show sustained therapeutic response to melanoma-specific treatment including BRAF inhibitors. BRAF mutational analysis should therefore be considered in cases of poorly differentiated sarcoma, especially if there is a known history of melanoma or with unusual localization of disease. The administration of melanoma-specific treatments in such dedifferentiated cases can show therapeutic response, highlighting the importance of rendering accurate diagnoses on such cases.

UR - http://www.scopus.com/inward/record.url?scp=85054908356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054908356&partnerID=8YFLogxK

U2 - 10.1038/s41379-018-0161-0

DO - 10.1038/s41379-018-0161-0

M3 - Article

C2 - 30315274

AN - SCOPUS:85054908356

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

ER -